生物谷報(bào)道： 韓國(guó)延世大學(xué)醫(yī)學(xué)院一個(gè)研究小組的科學(xué)家２５日宣布，他們發(fā)現(xiàn)可以使用藥物“特羅凱”治療無(wú)法用藥物“易瑞沙”治療的某類(lèi)肺癌患者,。
據(jù)韓國(guó)媒體報(bào)道，由延世大學(xué)醫(yī)學(xué)院腫瘤學(xué)科教授金周恒和趙柄哲領(lǐng)導(dǎo)的研究小組２５日表示,，對(duì)無(wú)法用“易瑞沙”（吉非替尼）治療的２１名非小細(xì)胞肺癌患者使用“特羅凱”（鹽酸厄替尼）治療后發(fā)現(xiàn)，有６名患者的存活期得到明顯延長(zhǎng)。
據(jù)研究小組科學(xué)家介紹，“易瑞沙”和“特羅凱”均屬于表皮生長(zhǎng)因子受體抑制劑,，它們主要用來(lái)治療肺癌,。因?yàn)閮烧叩淖饔脵C(jī)制相同,，此前韓國(guó)醫(yī)學(xué)界認(rèn)為，用“易瑞沙”治療無(wú)效的肺癌患者同樣不適合使用“特羅凱”治療,，因此很少用“特羅凱”替代“易瑞沙”進(jìn)行治療,。
這個(gè)研究小組稱(chēng)，新研究成果已被刊登在最新一期美國(guó)《臨床腫瘤學(xué)雜志》上,。（引自新華網(wǎng)）
原始出處:
Journal of Clinical Oncology, Vol 25, No 18 (June 20), 2007: pp. 2528-2533
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.10.4166
Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of Gefitinib
Byoung Chul Cho, Chong-Kun Im, Moo-Suk Park, Se Kyu Kim, Joon Chang, Jong Pil Park, Hye Jin Choi, Yu Jin Kim, Sang-Joon Shin, Joo Hyuk Sohn, Hoguen Kim, Joo Hang Kim
From the Yonsei Cancer Center; Department of Internal Medicine; Lung Cancer Clinic Severance Hospital; and the Department of Pathology, Yonsei University College of Medicine, Seoul, Korea
Address reprint requests to Joo Hang Kim, MD, PhD, Yonsei University College of Medicine, Seodaemun-gu shinchon-dong 134, Seoul, Korea; e-mail: [email protected]
Purpose: This study was designed to evaluate the efficacy and toxicity of erlotinib in patients with advanced non–small-cell lung cancer (NSCLC) who experienced disease progression after treatment with gefitinib.
Patients and Methods: The study included stage IIIB/IV recurrent or metastatic NSCLC patients who received two or three prior chemotherapy regimens and showed progressive disease within 4 months of gefitinib therapy discontinuation. Patients received erlotinib 150 mg/d until disease progression or unacceptable toxicity. Epidermal growth factor receptor (EGFR) mutations and other genetic abnormalities were analyzed from available tumor samples.
Results: Patient and disease characteristics (N = 21) included median age 56 years; number of prior chemotherapy regimens (three; n = 11); female sex (n = 11); adenocarcinoma (n = 15); and never-smoker status (n = 11). Among the 17 patients with tumor samples available, EGFR mutations were detected in five. The disease control rate (DCR) and response rate (RR) for all patients were 28.6% and 9.5%, respectively. The median duration of disease control was 125 days. The median time to progression and overall survival were 60 days and 158 days, respectively. Patients who had stable disease (SD) while receiving gefitinib showed significantly higher DCR (75% v 17.6% in non-SD patients; P = .050) and RR (50.0% v 0% in non-SD patients; P = .029). Among 17 patients with biomarker results available, those lacking EGFR mutations who had SD while receiving gefitinib showed significantly higher DCR and RR.
Conclusion: Erlotinib seems to be a potential therapeutic option for the treatment of advanced NSCLC patients with wild-type EGFR who had SD while receiving gefitinib.
B.C.C. and C.-K.I. contributed equally to this work.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
